We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
NVU | Nanoveu Limited | 0.045 | 0.0235 | 109.30% | 46,055,074 | 708 |
AAUO | Antilles Gold Limited | 0.002 | 0.001 | 100.00% | 8,375,000 | 4 |
A1G | African Gold Limited | 0.095 | 0.047 | 97.92% | 94,580,328 | 1,694 |
RSHO | Respiri Limited | 0.015 | 0.006 | 66.67% | 2,378,223 | 19 |
BNROA | Bulletin Resources Limited | 0.015 | 0.005 | 50.00% | 33,334 | 1 |
VRC | Volt Resources Limited | 0.005 | 0.0015 | 42.86% | 6,653,828 | 23 |
MTL | Mantle Minerals Limited | 0.002 | 0.0005 | 33.33% | 1,053,257 | 7 |
OVT | Ovanti Ltd | 0.004 | 0.001 | 33.33% | 4,633,234 | 6 |
VPR | Volt Group Ltd | 0.002 | 0.0005 | 33.33% | 1,750 | 1 |
SHO | Sportshero Limited | 0.017 | 0.004 | 30.77% | 381,932 | 10 |
EG1 | Evergreen Lithium Ltd | 0.066 | 0.015 | 29.41% | 303,507 | 17 |
MIAMI, Oct. 15, 2024 /PRNewswire/ -- Safe and Green Development Corporation (NASDAQ: SGD) ("SG Devco" or the "Company"), a leading real estate development company, announces that all site work has been completed for the first phase of its Sugar Phase I project in South Texas.
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024.
Sidus Space, Inc. (NASDAQ: SIDU), an innovative, agile space mission enabler, today announced that the U.S. Federal Communications Commission (FCC) has granted approval for the company to operate a micro constellation of remote sensing, multi-mission satellites in Low Earth Orbit (LEO).
Demonstrated Favorable Safety Profile of REQORSA AUSTIN, Texas, Oct. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the 0.09 mg/kg dose group of the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the Safety Review Committee (SRC) has approved escalation to the highest dose group of ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 66,042.39 | -14.51 | -0.02% | 1.3T | 5,568,475,057 |
ETH | Ethereum | 2,576.98 | -52.60 | -2.00% | 309.22B | 2,428,507,638 |
USDT | Tether USD | 0.99967 | 0.00003 | 0.00% | 119.61B | 303,442,852 |
BNB | Binance Coin | 589.39 | 0.358121 | 0.06% | 92.22B | 188,897,806 |
SOL | Solana | 154.08 | -3.37 | -2.14% | 71.71B | 984,769,956 |
USDC | USD Coin | 1.00 | 0.0003 | 0.03% | 35.55B | 1,236,237,818 |
XRP | Ripple | 0.5398 | -0.0086 | -1.57% | 30.41B | 243,077,090 |
STETH | stETH | 2,575.42 | -52.40 | -1.99% | 25.15B | 3,884,029 |
DOGE | Dogecoin | 0.11282 | -0.00387 | -3.32% | 16.42B | 306,530,808 |
TRX | TRON | 0.15822 | -0.002208 | -1.38% | 13.67B | 88,414,212 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions